Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
Status:
Completed
Trial end date:
2021-04-23
Target enrollment:
Participant gender:
Summary
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety,
and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have
undergone kidney transplant and have C3G recurrence (Cohort B).